Amneal Pharmaceuticals, Inc. reaffirmed earnings guidance for the year 2022. For the period, the company expects net revenue of $2.15 billion - $2.25 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.81 USD | +1.95% | +0.44% | +12.19% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.19% | 2.06B | |
+42.69% | 750B | |
+34.11% | 606B | |
-6.87% | 356B | |
+18.74% | 326B | |
+6.76% | 286B | |
+18.08% | 246B | |
-3.44% | 213B | |
+11.35% | 213B | |
+2.64% | 167B |
- Stock Market
- Equities
- AMRX Stock
- News Amneal Pharmaceuticals, Inc.
- Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2022